Pharmaceuticals, Vol. 13, Pages 90: Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents

Pharmaceuticals, Vol. 13, Pages 90: Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents Pharmaceuticals doi: 10.3390/ph13050090 Authors: Ahmed F. Salem Luca Gambini Parima Udompholkul Carlo Baggio Maurizio Pellecchia Recently, we reported on potent EphA2 targeting compounds and demonstrated that dimeric versions of such agents can exhibit remarkably increased agonistic activity in cellular assays compared to the monomers. Here we further characterize...

Pharmaceuticals

Sun May 10, 2020 03:00

Pharmaceuticals, Vol. 13, Pages 89: Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives

Pharmaceuticals, Vol. 13, Pages 89: Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives Pharmaceuticals doi: 10.3390/ph13050089 Authors: Loidreau Dubouilh-Benard Nourrisson Loaëc Meijer Besson Marchand We previously highlighted the interest in 6,5,6-fused tricyclic analogues of 4-aminoquinazolines as kinase inhibitors in the micromolar to the nanomolar range of IC50 values. For the generation of chemical libraries,...

Pharmaceuticals

Sat May 09, 2020 03:00

Pharmaceuticals, Vol. 13, Pages 88: Antibody Targeting of Eph Receptors in Cancer

Pharmaceuticals, Vol. 13, Pages 88: Antibody Targeting of Eph Receptors in Cancer Pharmaceuticals doi: 10.3390/ph13050088 Authors: Peter W. Janes Mary E. Vail Hui K. Gan Andrew M. Scott The Eph subfamily of receptor tyrosine kinases mediate cell-cell communication controlling cell and tissue patterning during development. While generally less active in adult tissues, they often re-emerge in cancers, particularly on undifferentiated or progenitor cells in tumors and the tumor...

Pharmaceuticals

Fri May 08, 2020 03:00